Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.38 |
| ▸ | NPY2R | P49146 | 1/20 | 0.38 |
| ▸ | NPY4R | P50391 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30618516 | 1.00 | GSR (0.42) | GSRCA1CA2CA4ALDH1A1 | |
| SCHEMBL26598048 | 1.00 | GSR (0.42) | GSRCA1CA2CA4ALDH1A1 | |
| SCHEMBL5699479 | 1.00 | GSR (0.42) | GSRCA1CA2CA4ALDH1A1 | |
| SCHEMBL8970301 | 0.98 | GSR (0.44) | GSRCA1CA2CA4ALDH1A1 | |
| SCHEMBL8969202 | 0.98 | GSR (0.44) | GSRCA1CA2CA4ALDH1A1 | |
| SCHEMBL23133685 | 0.95 | — | — | |
| SCHEMBL23108732 | 0.95 | — | — | |
| SCHEMBL8970449 | 0.95 | — | — | |
| SCHEMBL23425900 | 0.95 | — | — | |
| SCHEMBL23133681 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357271-A1 | MACROCYCLIC COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-11-09 | — | — | US | disclosed |
| US-20230357271-A1 | MACROCYCLIC COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-11-09 | — | — | US | disclosed |
| EP-4223368-A1 | MACROCYCLE COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2023-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357271-A1 | MACROCYCLIC COMPOUND | IRAK4, IRAK1, IRAK2 | GSR 4843/4885CA1 4610/4885CA2 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.